Premium
Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development
Author(s) -
Hussain Musaddique,
Xu Chengyun,
Ahmad Mashaal,
Majeed Abdul,
Lu Meiping,
Wu Xiling,
Tang Lanfang,
Wu Ximei
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1034
Subject(s) - ards , intensive care medicine , acute respiratory distress , medicine , drug , clinical trial , drug development , bench to bedside , respiratory distress , drug trial , pharmacology , medical physics , surgery , lung
Despite 50 years of extensive research, no definite drug is currently available to treat acute respiratory distress syndrome (ARDS), and the supportive therapies remain the mainstay of treatment. To improve drug development for ARDS, researchers need to deeply analyze the “omics” approaches, reevaluate the suitable therapeutic targets, resolve the problems of inadequate animal modeling, develop the strategies to reduce the heterogeneity, and reconsider new therapeutic and analytical approaches for better designs of clinical trials.